GlassScriptPhysician profile
Logan B Thrasher
NPI 1821560384
$22,195.81
in general payments reported to CMS, 2019-2025
31 companies · $4,781 in 2025
The $4,781 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,072 · 2022: $4,169 · 2023: $5,569 · 2024: $4,605 · 2025: $4,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,745.74 |
| Education | $209.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,330.30 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $2,363.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $2,038.99 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $2,038.44 | 2022-2025 | Auvelity |
| Abbvie INC. | $1,879.63 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,866.23 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,237.11 | 2021-2025 | Trintellix |
| Alkermes, INC. | $1,118.54 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,080.47 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,039.19 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $725.77 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $427.73 | 2021-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $311.23 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $259.96 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $249.44 | 2021-2024 | Adzenys Xr-Odt |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $218.50 | 2021 | |
| Eisai INC. | $157.96 | 2021-2022 | |
| Corium, LLC | $145.66 | 2021-2023 | Azstarys |
| Tris Pharma INC | $138.36 | 2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Bausch Health US, LLC | $119.18 | 2022-2023 | Aplenzin |
| Indivior INC. | $97.07 | 2021 | |
| Avanir Pharmaceuticals, INC. | $82.08 | 2022 | |
| Janssen Scientific Affairs, LLC | $63.65 | 2025 | Spravato |
| Noven Therapeutics, LLC | $50.55 | 2023-2024 | Xelstrym, Secuado |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.95 | 2025 | Rejoyn |
| Idorsia Pharmaceuticals US INC | $33.79 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $26.45 | 2021 | |
| Alfasigma USA, INC. | $16.28 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.80 | 2024 | |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Thrasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.